AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35237053
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g every 24 h for 5-7 days
Trial: 35237748
Drug: Nitazoxanide 600
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 600 mg twice daily for five days
Trial: 35238467
Drug: Matched therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched therapy recommended by the Molecular Tumor Board (MTB)
Trial: 35238615
Drug: Auricular acupuncture
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupuncture during chemotherapy infusion
Trial: 35239543
Drug: Pain medication,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain medication, preoperative anxiety, postoperative nausea and vomiting, and parent satisfaction were analyzed.
Trial: 35239732
Drug: Ferric citrate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferric citrate, initial dose adjusted to maintain serum phosphorus at 3.5-5.5 mg/dL, mean dose of 3.35±1.49 g/day (range 1.5 to 6.0 g/day)
Trial: 35241141
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of autologous, adipose-derived mesenchymal stem cells (adMSCs) at a dose of 2×10^6 cells
Trial: 35241141
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of autologous, adipose-derived mesenchymal stem cells (adMSCs)
Trial: 35241151
Drug: Human umbilical
RxNorm normalized name: Human umbilical tissue derived cells
DrugBank: Human umbilical tissue derived cells (DB17907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human umbilical cord MSCs injected twice into the uterus
Trial: 35241226
Drug: Therapeutic-dose enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic-dose enoxaparin
Trial: 35241240
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (HT) in females aged ≥60 years (N = 2,153, 47.6%)
Trial: 35241644
Drug: Branaplam, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branaplam, an orally available, brain penetrant small molecule
Trial: 35241844
Drug: 50 µg booster
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg booster injection of mRNA-1273
Trial: 35241942
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone (controlled-release 10 mg every 12 hours and immediate-release 5 mg every 4 hours as needed)
Trial: 35241942
Drug: Oral tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tramadol (controlled-release 100 mg every 8 hours and immediate-release 50 mg every 4 hours as needed)
Trial: 35242683
Drug: Neoadjuvant pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant pyrotinib 400 mg once daily, trastuzumab 4 mg/kg loading dose followed by 2 mg/kg once a week, and albumin-bound paclitaxel 125 mg/m2.
Trial: 35242798
Drug: Nutrient formulation
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nutrient formulation containing DHA, ARA, iron, vitamin B12, folic acid, and sphingomyelin from whey protein concentrate
Trial: 35243302
Drug: High-dose sevelamer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sevelamer (800 mg thrice daily, titratable up to 1,200 mg thrice daily)
Trial: 35243302
Drug: Low-dose sevelamer
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sevelamer (400 mg thrice daily) with calcium carbonate
Trial: 35243302
Drug: High-dose sevelamer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sevelamer
Trial: 35243302
Drug: Low-dose sevelamer
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sevelamer
Trial: 35243320
Drug: Booster CD-JEV
RxNorm normalized name: Jevtana
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Booster CD-JEV dose
Trial: 35244681
Drug: TAA-T infusions
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAA-T infusions at doses of 0.5 to 4 × 10^7/m2
Trial: 35244681
Drug: TAA-T infusions
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAA-T infusions
Trial: 35244820
Drug: Daily ECG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ECG TTM (30 s recordings)
Trial: 35244820
Drug: Daily ECG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ECG TTM
Trial: 35245341
Drug: Solid formulation
RxNorm normalized name: Corydalis solida whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid formulation of Vitamin B12 delivered during breastfeeding
Trial: 35245341
Drug: Solid formulation
RxNorm normalized name: Corydalis solida whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid formulation of Vitamin B12
Trial: 35246776
Drug: rhIL-7 ex
RxNorm normalized name: rhIL-7-hyFc
DrugBank: Efineptakin alfa (DB16395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-7 ex vivo administration
Trial: 35247086
Drug: Vorolanib 300
RxNorm normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorolanib 300 mg orally once daily plus pembrolizumab
Trial: 35247086
Drug: Vorolanib 300
RxNorm normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorolanib 300 mg orally once daily plus nivolumab
Trial: 35247086
Drug: Vorolanib 400
RxNorm normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorolanib 400 mg orally once daily
Trial: 35247086
Drug: Vorolanib 300
RxNorm normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorolanib 300 mg orally once daily
Trial: 35247086
Drug: Vorolanib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorolanib (300 or 400 mg)
Trial: 35247274
Drug: Pexidartinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexidartinib (200 mg single dose) in subjects with mild hepatic impairment
Trial: 35247274
Drug: Pexidartinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexidartinib (200 mg single dose) in subjects with moderate hepatic impairment
Trial: 35247913
Drug: Lenalidomide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (25 mg as the recommended phase II dose, taken orally for 21 consecutive days of 28-day cycles)
Trial: 35248212
Drug: Sofosbuvir-velpatasvir-voxilaprevir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir-velpatasvir-voxilaprevir (400 mg sofosbuvir, 100 mg velpatasvir, 100 mg voxilaprevir) once daily for 12 weeks
Trial: 35248213
Drug: Sofosbuvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (400 mg) and Velpatasvir (100 mg) once-daily for 12 weeks
Trial: 35248647
Drug: PDS 10
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PDS 10 mg/mL
Trial: 35248647
Drug: PDS 40
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PDS 40 mg/mL
Trial: 39209113
Drug: PDS 100
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PDS 100 mg/mL
Trial: 35248866
Drug: FCN-411 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-411 (4 mg, 8 mg, 12 mg, and 16 mg once daily until maximum tolerated dose)
Trial: 35248866
Drug: FCN-411 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-411 (8 mg once daily, recommended phase II dose)
Trial: 35248866
Drug: FCN-411 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-411 (all doses)
Trial: 35249485
Drug: AAV9-coGLB1 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AAV9-coGLB1 gene therapy, injected via caudal vein at 4 weeks of age, sustained expression for up to 32 weeks.
Trial: 35249540
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment for ADHD symptoms (specific medication not detailed)
Trial: 35249706
Drug: Propofol administered
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol administered via target-controlled infusion
Trial: 35250870
Drug: rhIGF-1 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF-1 treatment
Trial: 35251038
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in GLI activity by small molecule inhibitors or shRNA-mediated knockdown of GLI1 or GLI2.
Trial: 35251315
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m² in combination with everolimus
Trial: 35251320
Drug: Ribociclib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib + endocrine therapy (ET)
Trial: 35251346
Drug: Tinzaparin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin administered at an intermediate dose (8,000-12,000 Anti-Xa IU; once daily)
Trial: 35251346
Drug: Tinzaparin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin administered at a prophylactic dose (≤4,500 Anti-Xa IU; once daily)
Trial: 35251346
Drug: Tinzaparin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin (both doses)
Trial: 35253296
Drug: Information before
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information before rectal cancer surgery
Trial: 35253361
Drug: Defibrotide 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide 6.25 mg/kg IV q6h from the day prior to conditioning through day +21
Trial: 35253361
Drug: Defibrotide 6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide 6.25 mg/kg IV q6h
Trial: 35253443
Drug: Oral antithrombotic
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antithrombotic agents
Trial: 35254415
Drug: Taminadenant (80-640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taminadenant (80-640 mg, orally, twice a day)
Trial: 35254415
Drug: Taminadenant (80-640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taminadenant (80-640 mg, orally, twice a day) with spartalizumab (400 mg, i.v., every 4 weeks)
Trial: 35254416
Drug: INCB086550 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB086550 (a small-molecule PD-L1 inhibitor)
Trial: 35255140
Drug: CoronaVac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac vaccine (2 doses, 8-12 weeks before enrollment)
Trial: 38381948
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral pre-exposure prophylaxis (PrEP)
Trial: 35256316
Drug: MF-directed monotherapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF-directed monotherapy (hydroxyurea or ruxolitinib)
Trial: 35256525
Drug: No lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lipid-lowering treatment
Trial: 35256693
Drug: Thionamide anti-thyroid
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thionamide anti-thyroid drug (titration dosing regimen)
Trial: 35256844
Drug: Treatment preferences
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment preferences based on avoiding severe nerve damage and longer progression-free survival (PFS)
Trial: 35256844
Drug: Cost implications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost implications on treatment preferences
Trial: 35257639
Drug: Combined isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined isoflavone compound (CIC)
Trial: 35257949
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg/30 mg once daily with pembrolizumab 200 mg every 3 weeks
Trial: 35258804
Drug: Pre-implant assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-implant assessment
Trial: 35258804
Drug: Post-implant assessment
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-implant assessment
Trial: 35258841
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 14 mg daily
Trial: 35258987
Drug: Temozolomide followed
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide followed by low-dose ipilimumab and nivolumab
Trial: 35259629
Drug: Waiting neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting neoadjuvant chemotherapy in resectable tumours during lockdown
Trial: 35259629
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of mFOLFIRINOX preoperative chemotherapy regimen during lockdown
Trial: 35260030
Drug: Exposure based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure based cognitive behavioral therapy (ECBT)
Trial: 35260178
Drug: Implantable ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable ultrasound device (SonoCloud-1) with 1-MHz frequency, used in combination with intravenous infusion of microbubbles, administered over 3.5 months with seven ultrasound sessions (twice per month).
Trial: 35260458
Drug: VAC52150 (Ad26.ZEBOV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC52150 (Ad26.ZEBOV, MVA-BN-Filo) two-dose vaccine regimen, doses given 56 days apart.
Trial: 35260458
Drug: Delayed second
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed second dose of VAC52150 (Ad26.ZEBOV, MVA-BN-Filo) vaccine.
Trial: 35260879
Drug: ABBV-085 antibody-drug
RxNorm normalized name: antibody-drug conjugate DP303c
DrugBank: DP-303c (DB17212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-085 antibody-drug conjugate (ADC)
Trial: 35260913
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg on days 1 and 15, Irinotecan 125 mg/m²
Trial: 35260962
Drug: Induced Hypertension
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induced Hypertension (iHTN) via norepinephrine infusion in 20-mm Hg increments
Trial: 35484319
Drug: Avelumab 20
RxNorm normalized name: avelumab 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab 20 mg/kg intravenously every 2 weeks
Trial: 35262846
Drug: Milvexian 60
RxNorm normalized name: Milvexian
DrugBank: Milvexian (DB16233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian 60 mg
Trial: 35263188
Drug: Extended Infusion
RxNorm normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended Infusion Set
Trial: 35263963
Drug: filgotinib 100
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: filgotinib 100 mg
Trial: 35264341
Drug: Surgical treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatments for AEDH (including craniotomy and DC)
Trial: 35264424
Drug: sNfL levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sNfL levels at preataxic stage (median 15.5 pg/mL [interquartile range 10.5-21.1 pg/mL])
Trial: 35264424
Drug: sNfL levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sNfL levels at ataxic stage (31.6 pg/mL [26.2-37.7 pg/mL])
Trial: 35264424
Drug: sNfL levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sNfL levels in controls (6.0 pg/mL [4.7-8.6 pg/mL])
Trial: 35264434
Drug: Ziv-aflibercept 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziv-aflibercept 4 mg/kg plus pembrolizumab 2 mg/kg every 2 weeks
Trial: 35264559
Drug: ImmunoPET imaging
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ImmunoPET imaging using a radiolabeled HIV Env-specific broadly neutralizing antibody
Trial: 35266046
Drug: Energy drink
RxNorm normalized name: Boost Energy Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy drink (240 mg caffeine)
Trial: 35266046
Drug: Coffee (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee (240 mg caffeine)
Trial: 35266065
Drug: Quantum Magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quantum Magnetic Resonance Therapy (QMRT)
Trial: 35266624
Drug: Sustained virological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained virological response (SVR-12) with direct-acting antiviral agents (DAAs)
Trial: 35266655
Drug: Topical recombinant
RxNorm normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical recombinant nerve growth factor (cenegermin)
Trial: 35267143
Drug: Perceiving negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceiving negative interferences of cancer in daily life
Trial: 35267535
Drug: Multitask learning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multitask learning of pre-/mid-treatment FDG-PET radiomics
Trial: 35267579
Drug: 13.56 MHz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13.56 MHz modulated electro-hyperthermia (mEHT) boost during neoadjuvant treatment, twice a week during radiotherapy
Trial: 35268478
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg) administered 24 hours before surgery and on days 2, 3, 4, and 5 postoperatively.
Trial: 35268478
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered on the same schedule as colchicine.
Trial: 35270262
Drug: CoVQuest-CC Questionnaire
RxNorm normalized name: FORMIC ACID 14.5 g in 100 g TOPICAL GEL [Provita Konquest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoVQuest-CC Questionnaire
Trial: 35272132
Drug: Cabazitaxel (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (25 mg/m² administered intravenously)
Trial: 35272845
Drug: Mobility, nutrition,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobility, nutrition, medication use, physical functioning, and self-rated health before surgery.
Trial: 35272946
Drug: Cancer drug
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer drug repurposing for PIK3CA-driven overgrowth
Trial: 35274209
Drug: Continuous wound
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous wound infusion combined with intrathecal morphine
Trial: 35274209
Drug: Continuous wound
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous wound infusion alone
Trial: 35274717
Drug: Pembrolizumab in
RxNorm normalized name: pembrolizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab in combination with capecitabine and oxaliplatin (CAPOX)
Trial: 35274722
Drug: D-0316 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-0316 (50 mg)
Trial: 35274722
Drug: D-0316 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-0316 (100 mg)
Trial: 35275019
Drug: Dynamic gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic gallium 68 imaging (details on dosage and duration not provided)
Trial: 35275108
Drug: DEPITAC questionnaire
RxNorm normalized name: TAPE,SILICONE MEPITAC 0.75INX3YD #298300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEPITAC questionnaire administered by nurses
Trial: 35275599
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) initiated in Fiebig 1 acute HIV infection
Trial: 35275599
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) initiated in later Fiebig stages
Trial: 35275734
Drug: Father-focused childhood
RxNorm normalized name: Gallus gallus feather
DrugBank: Gallus gallus feather (DB10420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Father-focused childhood obesity prevention program, details on dosage and duration not available
Trial: 35276694
Drug: Multi-kinase/PDGFRβ inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-kinase/PDGFRβ inhibitors
Trial: 35276694
Drug: HDAC inhibitors
RxNorm normalized name: Hdac inhibitor cxd101
DrugBank: CXD101 (DB16182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDAC inhibitors
Trial: 35277389
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of CoronaVac vaccine
Trial: 35279084
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control (standard-of-care antibiotics)